Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Bendamustine Superiority in Lymphoma Regimen Confirmed

June 3rd 2012

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

June 2nd 2012

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

May 30th 2012

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Photopheresis Process Offers Relief From Lymphoma Lesions: An Interview With Dennis Parenti, MD

May 24th 2012

To learn more about how photopheresis can help patients fight the symptoms of CTCL, OncologyLive spoke with Dennis Parenti, MD, vice president of Clinical Affairs for Therakos.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Taking the Long View: Imatinib Success Story Stands the Test of Time

May 22nd 2012

The demonstrated impact of imatinib mesylate on outcomes for patients with CML shifted the oncology paradigm to an intensive search for relevant molecular target.

May 2012: Trials in Progress

May 14th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Ansell on Waldenström Macroglobulinemia Treatments

May 11th 2012

Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia

Meeting the Challenges in Treating Lymphoma: A Conversation With Andrew D. Zelenetz, MD, PhD

May 8th 2012

Discussion with Andrew D. Zelenetz, MD, PhD, on a number of new therapies and interesting challenges regarding the treatment of patients with both Hodgkin and non- Hodgkin lymphoma.

Dr. Erba Discusses Molecular Monitoring for CML

May 8th 2012

Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML

Michael Eckenfels on Bortezomib Delivery Route Changes

May 5th 2012

Michael Eckenfels, RN, OCN, from MD Anderson Cancer Center, on Changes to the Bortezomib Delivery Route.

Emerging Markers Point to Future Strategies in CLL: An Interview With William G. Wierda, MD, PhD

April 27th 2012

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Dr. Zelenetz Discusses Treatment Options for DLBCL

April 26th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Treatment Options for DLBCL

Novel Treatments for Chronic Lymphocytic Leukemia

April 20th 2012

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

Beyond R-CHOP-21: What's New in Diffuse Large B-Cell Lymphoma

April 19th 2012

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

April 2012: Trials in Progress

April 17th 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Dunleavy Discusses Treatment Options for PMBL

April 16th 2012

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses Treatment Options for Primary Mediastinal B Cell Lymphoma

How Fellows Can Add Value to Their Internal Medicine Residency Program

April 15th 2012

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.

(Never) A Typical Day in the Life of a Pediatric Hematologist/Oncologist

April 15th 2012

There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.

Elotuzumab Responses High in Multiple Myeloma Study

April 12th 2012

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

NEXT PAGE
PREVIOUS PAGE